H., Wolf, P., Vila, G., & Luger, A
Variants in FTO (fat-mass and obesity-associated), GLP1R (the GLP-1 receptor itself), MC4R (a satiety and energy-balance receptor), and TCF7L2 (tied to glucose handling and GLP-1 secretion) describe the metabolic terrain a clinician is prescribing into
Friedreich ataxia (FRDA) FRDA is a fatal neurodegenerative disorder characterized by progressive motor coordination deficits and hypertrophic cardiomyopathy, with its pathological core involving dysfunction of Fe-S enzyme systems and mitochondrial iron metabolism imbalance [104]
Its moderate energy density, coupled with functional versatility, expands its applicability across specialized nutritional strategies, including weight management programs and metabolic conditioning protocols
Es ist eine Forschungsverbindung es ist kein Arzneimittel und besitzt keine Zulassung fr die klinische Anwendung in Deutschland oder der EU